Despite setbacks in the past and apparent hurdles ahead, gene therapy is advancing toward reality. The past several years have witnessed this new field of biomedicine developing rapidly both in breadth and depth, especially for the treatment of cancer, thanks largely to the better understanding of molecular and genetic basis of oncogenesis and the development of new and improved vectors and technologies for gene delivery and targeting. This article is intended to provide a brief review of recent advances in cancer gene therapy using adenoviruses, both as vectors and as oncolytic agents, and some of the recent progress in the development of immunotoxins for use in cancer gene therapy.
Introduction
Gene therapy, initially hailed as a revolutionary biomedical technology with enormous potential for curing almost any disease, has come a long way on a turbulent course in a relatively short period of two decades. Its original concept for treating disease by replacing a lost or defective gene has broadened to encompass a variety of approaches of introducing genetic materials into cells for therapeutic purposes. A large number, nearly 1000, gene therapy clinical trials have been or are being conducted worldwide, and two-thirds of these are for cancer. 1 While the technology itself is still evolving, gene therapy is particularly suitable for cancer, since most patients with cancer who are eligible for clinical trials, are terminal with poor prognosis and dismal outcomes due to failing conventional treatment. Thus gene therapy, with its limited efficacy (in part due to the late stage of disease at which patients are treated in clinical trials) and sometimes severe side effects, often provides the best or the only alternative for patients who are refractory to conventional treatments. In addition, the lower cost of gene therapy when compared with conventional treatments makes it especially attractive particularly to patients with limited financial means and those in developing countries.
Cancer gene therapy has made remarkable progress over the past few years, reaching some significant milestones. The first cancer gene therapy clinical trial was performed in the early 1990s 2 in the US; however, in China it was 10 years later -in the Spring of 2004 -that the first therapeutic gene, adenovirus (Ad)-p53, was approved for commercial use by China's State Food and Drug Administration (SFDA) for head and neck squamous cell carcinoma (HNSCC). Gendicine is a biologically active, replication incompetent, recombinant Ad-p53, and has been used in clinical trials for hepatocellular (HCC), nasopharyngeal (NPC), gastric, liver, lung, breast, prostate and ovarian cancers in addition to HNSCC. 3 The infectivity of the virus is limited to one cycle and the Ad vector does not integrate into the host genome. Doses are 1-4 virus particle units (v.p.u.)/ injection/week usually for 4 consecutive weeks. Side effects have been predominantly self-limited fever in 32% of patients and responses to date have been in patients often refractory to conventional treatments. Some of the best results with this treatment have been seen when Gendicine has been used in combination with conventional treatments such as with radiation to treat NPC 3 or with transcatheter hepatic arterial chemoembolisation to treat HCC. periods of time by the US military. Human AdV-4 and HAdV-7 were shown to be the cause of epidemics of acute respiratory disease in US military recruits in the 1950s. 5 In response, live hAdV-4 and hAdV-7 vaccines were developed which constituted of lyophilized virus encapsulated in an enteric coat and were administered as an oral tablet. This vaccine strategy was shown to be effective and disruptions in vaccination were shown to lead to resurgences in the disease 6, 7 at various time points over the past four decades. This vaccine has been shown to have high safety indexes and represents the most successful application of an (live) Ad in a therapeutic setting to date, 8 which also provides safety basis for Ad-based gene therapy.
Two years after the SFDA approved Gendicine, the first oncolytic Ad, H101, was approved by the SFDA as a commercial gene therapy treatment. H101 is used in combination with local heat treatment and chemotherapy for the treatment of late stage refractory NPC, another type of head and neck cancer. To date, H101 has been shown to improve survival rates particularly when used in combination with conventional treatments in patients refractory to conventional treatment. 9 Here we will review some of the recent developments and highlights of replication-defective Ad vectors, conditionally-replicative (oncolytic) adenoviruses (CRAds) and immunotoxins for clinical cancer gene therapy. For more detailed discussions and background on these topics, the readers are referred to several excellent recently published reviews. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Adenoviruses (Ads)
Since their initial description in the early 1950s, 5 Ads have been extensively characterized, originally as pathogens that cause common colds, and depending on the infecting serotype the cause of other illnesses such as gastroenteritis, conjunctivitis, cystitis or respiratory illnesses. Later, Ads were used as a tool for the investigation of mammalian molecular and cellular biology, and especially as a key vehicle for gene therapy. 20 However, there is still much to be learned about the mechanism of infection and life cycle of Ads, particularly their interactions with the infected host, and there is room for improvement before it can be considered an ideal gene transfer vector.
Ads are non-enveloped DNA viruses. Over 50 serotypes of human Ads are known, among which Ad2 and Ad5 are the most common and from which most of the current Ads in gene therapy are derived. The icosahedral capsid of Ads consists of three major proteins, hexon (Protein II), penton base (Protein III) and a knobbed fiber (Protein IV), the latter two making up the so called penton complex, along with a number of other minor proteins 21 ( Figure 1a ). The genome of Ads is a linear, doublestranded DNA of approximately 36 kb flanked by two short inverted terminal repeats that serve as origins of replication, and containing overlapping transcription units on both strands encoding over 50 polypeptides and a set of RNAs (VA RNAs) that are not translated but play an essential role in combating cellular defense mechanisms. 22 Based on the time course of their expression during the virus life cycle, Ad genes are classified into four major groups: early region (E1A, E1B, E2 to E4), delayed units (IX and IVa2), late region (L1 to L5) and VA regions (Figure 1b) .
Ad infection is initiated by binding of the fiber knob domain to a cell surface receptor which is CAR (coxsackie-Ad receptor) for most serotypes, followed by interaction of the penton base with integrins. After entry through receptor-mediated endocytosis, the virus escapes from the endosome to the cytosol and releases its genome into the nucleus where viral transcription and replication occur. The Ad infectious cycle can be divided into two phases separated by viral DNA replication. The entry of the virus into the host cell, the passage of the virus genome to the nucleus and selective expression of the early genes occur in the 'early' phase, which sets the stage for the viral DNA replication. Replication of viral DNA is followed by expression of the late genes in the 'late' phase. This leads to the assembly in the nucleus of the structural proteins and the maturation of infectious virus. 22 Completion of the infectious cycle by the (replicative) virus triggers cytolysis and the release of virion progeny.
The early gene products play many important roles in the viral transcription, DNA replication and interaction with cellular machinery. Among them, E1A is the first gene expressed after viral infection and the most important transcriptional activator for subsequent viral gene expression. E1A interacts with retinoblastoma protein (pRb) and many other cellular proteins, and induces cell cycle entry, thus promoting viral replication, but it also activates the apoptosis pathway.
23 E1B-55kD binds to p53 and induces its degradation preventing apoptosis, while E1B-19kD also acts like an antiapoptotic factor, together both prevent the death of the infected cell allowing viral replication to occur. Other early genes encode proteins required for: viral DNA synthesis (E2); regulation of viral DNA replication, mRNA transport and apoptosis (E4); and host immune suppression and cell lysis (E3). The delayed and late genes encode viral structural proteins and the proteins necessary for virus assembly. 24 
Ads as gene therapy vectors
The primary challenge for the vector-based gene therapy of cancer or any disease is how to develop vectors that enable a dose of the therapeutic gene(s) to be delivered to and expressed in the diseased tissues with high efficiency, specificity and safety. The diverse malignancies that are potential targets for gene therapy necessitates vectors of varying properties. Vectors commonly used in cancer gene therapy are engineered from viruses, including mainly retroviruses, Ad, adeno-associated viruses (AAV), lentiviruses (LV) and herpes simplex viruses (HSV). Advantageous attributes, such as high infectivity of most mammalian cell types (both dividing and quiescent), high expression level of the transgene(s), ease for achieving high virus titer and replication deficiency, large capacity for accommodating transgene(s) and non-integration into the mammalian genome, have made Ads one of the most widely used gene transfer vectors today. 18 Nevertheless, Ad vectors are highly immunogenic inducing strong host immune responses that can rapidly eliminate transgene expression, 25 which, along with the fact that the vectors remain epichromosomal, renders transgene expression shortlived. In cancer gene therapy, potent immunogenicity may be desirable because it may enhance antitumor effects, 26 but strong immune responses may also cause harmful effects to the patient, whereas the transient duration of transgene expression is clearly a shortfall of Ad-based therapy for long-term gene therapy treatments. Furthermore, expression of the primary receptor for Ads, CAR, is variable and frequently low 27 Various strategies have been attempted to overcome these obstacles. Deletion of more Ad genes, from E1 and E3 to E2 or/and E4, has reduced immunogenicity. The most striking version is the so called 'gutless' Ad, which is made devoid of all viral coding regions. Several animal studies have shown that this new generation Ad vector elicits a much reduced in vivo immune response and prolongs transgene expression, while maintaining relatively high transduction efficiency and wide tropism. 28, 29 However, without its own viral genes, the gutless vector requires the help of a helper virus to produce viral particles, which gives rise to a new problem of contamination with helper viruses. Up until now, contamination levels have been too high for these to be used in clinical trials, and it is difficult to achieve the production and purification of gutless Ad in quantities sufficient for clinical use. Thus, further advances are still needed before it could be applied in clinical treatments. 10 A recent report 30 described an Ad-alphavirus hybrid vector designed to take advantage of the high infectivity of Ads for hepatic cells, the high level of protein expression and proapoptotic properties of Semliki Forest virus (SFV) replicon and tumor selectivity of the alphafetal protein (AFP) promoter, for use in the treatment of HCC. This vector is composed of a helper-dependent Ad containing an SFV replicon under the transcriptional control of an AFP promoter and a transgene driven by the SFV subgenomic promoter. Experiments with the vector in vitro and in an HCC model showed that the treatment of established tumors with the hybrid vector carrying mIL-12 resulted in enhanced rodent survival without toxicity suggesting this type of vector is potent and safe.
As vectors for cancer gene therapy, replication-defective Ads have been commonly used to transfer tumorsuppressor genes, anti-angiogenic factors, prodrugactivating genes and immunostimulatory genes. 1, 17, 18 More recently, a number of approaches employing Ad vectors to deliver different types of genetic material have emerged, of which some are shown in Table 1 .
Ad-based antisense/small interfering RNA therapy. Ad vectors have been applied to gene therapy as a mechanism for gene silencing. Ads are traditionally used to carry single-stranded antisense oligonucleotides (ASOs) toward a given targeted gene to achieve gene silencing. By inserting in reverse sense partially cloned sequences for the targeted gene and transfecting cells with the recombinant Ad-based vectors, the antisense RNA for the targeted gene is produced resulting in the subsequent knockdown of the targeted message. Various studies have been conducted over the years to identify molecules that specifically and optimally silence different target genes, most of which have been oncogenes, and their effects are usually tested at the cellular level. For example, Ads expressing the antisense c-myc fragment were shown to suppress cell proliferation and induce normal differentiation cycles in HL-60 cells, 31 and Ads simultaneously expressing both antisense ornithine decarboxylase and adenosylmethionine decarboxylase were shown to inhibit colorectal cancer cell growth in vitro.
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More recently, making use of RNA interference (RNAi), Ad vectors are being employed to deliver small interfering RNA (siRNA) molecules in the form of short hairpin RNAs (shRNAs), resulting in gene silencing. This new approach appears more workable and robust than ASO techniques in terms of consistency of transcript knockdown and threshold concentration, 33 and offers the opportunity to improve the successful suppression of the target gene. In a recent report, Ad-delivered shRNA molecules have been shown to effectively silence endogenous TGFbRII while a set of Ad-delivered antisense RNA fragments failed to do so. 34 A further strategy would be to use tumor-specific, conditionally replicative Ads (CRAds, see below) to carry ASOs or siRNAs, which can make the expression of the gene silencers specific and long lasting in the tumor tissues, and combine the dual benefits of the viral oncolysis of Ads and ASO/siRNAmediated target gene silencing.
Ad-based cancer vaccines
Gene-based vaccination has emerged in recent years as one of the highly promising approaches for cancer gene therapy. In addition, Ad has often been chosen as the vector to carry cancer cell-associated antigens and/or other immunostimulatory cytokines in the development of gene-based cancer vaccines. Compared with traditional vaccines, cancer vaccines are more complex in that they need to readjust an antigen-experienced immune system to be more sensitive to a specific, and often weakly immunogenic tumor-associated antigen, while a variety of tumor-associated antigens can evade the immune response by a complex immune tolerance mechanism probably because most of them are 'self' antigens occurring in normal cells. Additionally, tumor cells which survive selectively escape immune surveillance by several mechanisms as they evolve, primarily through the reduced expression of tumor-specific antigens, antigen-presenting molecules, downregulated costimulatory molecules such as MHC Class I via the E3-19K gene product MHC, 35, 36 the overexpression of nonmutated self proteins (such as defined lineage-specific antigens in melanoma), the presence of antigen-specific T cells with low avidity and through the inhibition of the induction and maturation of dendritic cells (DCs). 37, 38 However, vaccines targeting foreign antigens in virus-caused cancers do not encounter the same problems of self-tolerance.
A basic Ad-mediated cancer vaccine consists of an Ad vector and a tumor-associated antigen gene(s) which is delivered directly to the host. A variation of this has been to use the recombinant virus to infect cancer cells which are then lethally irradiated before delivery to the host. Significant improvements could be generated through the addition of immuno-stimulatory genes to the vaccines, and even greater improvements achieved through the transduction of antigen presenting cells (APCs) ex vivo with the recombinant virus before delivering the live cells to the host. Furthermore, strategies can be extended to deliver both the recombinant virus and the loaded cells to patients.
Ads as tumor vaccine vehicles offer potential advantages for delivering tumor-associated antigens and immunomodulatory molecules at high local concentrations, promoting effective processing and MHC expression and stimulating potent cell-mediated immunity. 39, 40 Encouraging results have been reported from an increasing number of preclinical and clinical studies using Ad-mediated cancer vaccines employing some of the strategies mentioned. For example, E1 and E2a-deleted Ad carrying breast tumor antigen HER2/neu (p185), when produced in vitro and directly injected into an animal tumor model, showed preventive antitumor effects and therapeutic effects only if prime-boosting was used with the plasmid counterpart being utilized in the priming phase. 41 Ads containing a modified, secretable form of tumor-derived antigen GRP94 (AdsGRP94) was used to infect tumor cells which were then lethally irradiated. This vaccine could elicit preventive antitumor effects, but had minimal effects on established tumor models unless vaccination was combined with an intra-tumoral injection of AdsGRP94 and radiation therapy. 42 Ad-mediated cancer vaccines appear to be more effective when tumor-associated antigens are coexpressed or delivered along with lymphokines and/or other immunostimulatory genes such as IL-2, IL-12, TNFa, and CD40 ligand. [43] [44] [45] At present, the most widely adopted and possibly the most promising strategy has been to transduce DCs ex vivo with Ads harboring the genes for antigens and immune regulatory factors and then implanting the engineered DCs into the host. Since DCs are the most important and effective APCs, this approach allows a sustained high concentration of the antigens to be processed and presented more efficiently, eliciting potent cellular and humoral immune responses, which are necessary for combating established solid tumors. Recent examples include DCs transduced ex vivo with Ad vectors encoding the tumor associated antigens human telomerase (hTERT), 46 mucin-1, 47 5T4 oncofetal antigen, 48 carcinoembryonic antigen (CEA), 49 mutant K-ras 50 or in combinations, HER-2/neu and TNFa 51 , E7 and Other genes TNF-a, E1A, anti-MDR1 ribozyme, etc.
Induce tumor cells to become susceptible to radiotherapeutics, revert multidrug resistance of tumor cells, etc.
Breast, rectum, liver, etc. 17, 140, 141 Abbreviations: PTEN, phosphatase and tensin homolog deleted on chromosome 10; hMUC1, human mucin/human polymorphic epithelial mucin; IFN-g, interferon gamma; TNF-a, tumor necrosis factor alpha; VEGI, vascular endothelial growth inhibitor; CD, cytosine deaminase.
4-1BBL,
52 gp100 and IL-12, 53 gp70 and IL-12 and/or GM-CSF (granulocyte macrophage-colony-stimulating factor), 54 which were each shown to be able to induce significant antitumor cytotoxic T lymphocyte responses and antitumor immunity.
However, the efficacy of the current Ad-mediated, gene-based vaccination strategies is still limited in patients, especially those with well-established tumors, and these are not yet effective enough to justify wide-scale clinical applications. 55 Besides the efforts that are underway to increase the transduction efficacy for use with DC and to induce high levels of transgene expression, further modifications to improve Ad-mediated vaccines are needed to avoid vector-related immune responses which result in tissue inflammation and injury, viral neutralization and premature clearance of the Ad-transduced cells. 39 In general, the convergence and combination of different strategies appears to be the right direction to take.
Modifications to improve the targeting of Ad vectors
Modification of the capsid fiber and penton base protein for targeting. A direct approach to achieving vector targeting central to the success of many Ad-based gene therapy applications is to alter viral tropism through the genetic modification of the tropism-determining capsid proteins particularly the capsid fiber as well as the penton base and protein IX (pIX) (Figure 2 ). The antenna-like trimeric fiber and pentameric penton base are the two oligomeric components of the penton complex of the Ad capsid which bind to cellular receptors and determine tropism. The initial step in infection by Ad is the binding of the primary cellular receptor CAR by the globular knob of the fiber, then the penton base recruits avb integrins via an RGD (Arg-Gly-Asp) motif, leading to internalization of the virion via receptor-mediated endocytosis. Consequently, genetic manipulations to alter Ad tropism have directed largely at the fiber and penton base, and various modifications have been made to the proteins with appreciable success in specific targeting but without structural or functional perturbation of Ad vectors. 56 Incorporation of ligands such as RGD and polylysine (pK) motifs, for targeting integrins and heparin receptor, respectively, at the fiber knob's C-terminus or HI-loop was shown to improve CAR-independent transduction while expanding Ad tropism, 57, 58 with the latter locale permitting inserts of a larger size (up to 100 residues). Replacement of the knob or the whole fiber with various ligand fusions containing a trimerizing domain from other viral or nonviral proteins that could form a trimeric structure similar to the knob was able to both ablate the Ads native CAR tropism and confer a ligand-based alternate tropism, [59] [60] [61] so was switching the knob or fiber with serotypes of Ads with non-CAR receptors. 62, 63 The penton base was modified for specific targeting by incorporation of ligands, 64 or for detargeting away from cells with the RGD-binding integrins by mutation of its RGD motif. 65, 66 Modification of capsid pIX for specific targeting. pIX is an abundant (240 copies) and small polypeptide (140 residues) which is an essential part of the Ad capsid. It helps stabilize hexon-hexon interactions on the capsid surface and maintain the overall structure and thermal stability of the virion. It appears essential for packaging Ad DNA, and works as a transcriptional activator of several viral and cellular TATA-containing promoters, likely contributing to the transactivation of the Ad expression program. 67 Nonetheless, pIX is dispensable for viral replication and structurally dispensable during virion formation.
Being exposed on the outer surface of the viral capsid, the C terminus of pIX has become an attractive site for incorporation of targeting ligands. 67 Several such ligands (sized up to 300 amino acid residues) have been incorporated efficiently in the pIX ectodomain and evaluated, including heparan sulfate-binding pK motif, 68 and integrin-binding RGD motif 69 (and recently singlechain fragment variable (scFv) fragments of antibodies recognizing tumor-specific receptors), which were properly expressed on the capsid surface and enhanced transduction of CAR-deficient cells via binding with their respective receptors on the cell surface. In addition, placing a-helical spacers up to 75Å in length between ligands and pIX tended to increase the accessibility of the ligands.
69
Bi-specific adapter for Ad targeting. Another strategy of transductionally targeting Ads is through the use of a bispecific adapter consisting of a domain which interacts with the virus capsid and another domain that recognizes and binds to the cell surface receptor 70 (Figure 2) , in which modification of the Ad capsid components which are not required and the purified hybrid adapter can be mixed with Ad particles for infection or expressed from Ad. Bispecific adapters composed of the amino-terminal extracellular domain of the human CAR protein (CARex, sCAR) and the Fc region of the human immunoglobulin G1 protein, 71 of sCAR, phage T4 fibritin polypeptide (trimerizing domain) and C6.5 scFv against c-erbB-2 oncoprotein, 72 and of a bacterially expressed single-chain diabody, scDbMelAd, that binds to both the adenoviral fiber protein and to the high molecular weight melanomaassociated antigen (HMWMAA), 73 were shown to be effective in re-directing Ad to transduce cells expressing the targeted receptor in a CAR-independent manner. An interesting variation to the strategy has been to use a bispecific adapter for Ad to cross blood-brain barrier (BBB) by re-directing Ad to P97 transcytosis pathway with a bispecific adapter consisting of sCAR and P97, a transferring homolog known to cross BBB effectively and accumulate in the brain. In in vitro studies, the adapter protein appeared to be able to re-direct Ad5 particles to the P97 transcytosis pathway and cross the BBB. 74, 75 AAV/Adv 'cocktail' vector system. The major strengths and limitations of Ad and AAV vectors are complementary. The integrative AAV does not have the problems associated with Ads which can cause strong inflammatory responses and a transitory expression of therapeutic genes, but it has a low transduction efficiency. Earlier work has shown that Ad was able to enhance AAV transduction, evidently via promoting the second-strand DNA synthesis of AAV by ORF6 from E4 of Ad. 76 Based on these, an AAV/Ad 'cocktail' vector strategy was endeavored recently. It was shown that addition of a low level of Ad-bone morphogenetic protein 2 (BMP2) to AAV-BMP2 produced significantly higher new bone formation than the use of AAV-BMP2 alone in the rat model. 77 Studies are underway to examine the application of this strategy in cancer gene therapy. 78 Oncolytic, conditionally replicative Ads As pathogens, Ads have evolved an inherent ability to replicate in the host and lyse cells. It has been realized early on that such cytotoxic effects of Ads may also be harnessed for therapeutic purposes. In light of the limited success of nonreplicative Ad vectors in cancer gene therapy, researchers have recently refocused their work on the historic concept of virus oncolysis, that is, destruction of tumor cells via viral replication, which has led to a rapid increase in the number of clinical trials using them in recent years. Compared with other types of viruses, Ad has a number of advantages for use as oncolytic viruses. In addition to most of the advantages mentioned above for Ad vectors, Ad is well-characterized, highly amenable to genetic manipulation; its wild type causes relatively mild disease; there is considerable clinical trial experience and several trials have demonstrated the safety and clinical activity of conditionally replicative Ads (CRAds). [79] [80] [81] [82] By exploiting the features associated with tumors and the cellular defects that promote tumorigenesis, CRAds are designed with the ability to selectively replicate in the target tumor cells but not in normal tissues. CRAds usually kill tumor cells by oncolysis directly induced by the replicated Ads instead of by the genes delivered in the vectors, however, 'armed' CRAds carrying therapeutic genes such as cytokines, 83 suicide or prodrug activating genes, 84, 85 anti-angiogenic genes, 86 antisense RNAs, 87 siRNAs against oncogenes or inhibitors of oncolysis, 78, 88 for example, are being developed to make full use of Ads as both the 'warhead' and the 'vehicle'. Additionally, amplified viruses can be spread to the adjacent tumor cells and kill these cells in the same manner. Their administration via multiple routes and in combination with chemo-or radio-therapies, has been demonstrated to be mostly safe.
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The selectivity of CRAds is crucial for its tumorspecific targeting. Generally, the selectivity of CRAds for cancer cells can be achieved either during infection or during replication (Figure 2) . According to the different mechanisms of selectivity, CRAds can be divided into four classes: CRAds (1) with tumor-selective infectivity; (2) with tumor-selective replication; (3) with replication driven by tumor-specific promoters; and (4) with combined tumor selectivity.
Tumor-selective infection. As mentioned above, tropism of Ad is determined by the interactions of the capsid proteins with cell surface receptors, the major components of which include the capsid fiber that recognizes CAR (the primary cellular receptor for Ad which is lacking in many tumors), and the penton base which contains the integrin-binding site. On the other hand, epidermal growth factor receptor (EGFR) is specifically overexpressed in many types of tumor cells, and some tumors preferentially express certain integrins that can bind RGD peptides. Accordingly, tumor-selective infection with CRAds can be achieved through the manipulation of the interactions between the capsid and the cell surface by altering viral surface proteins (such as the fiber knob, penton base, pIX protein) or providing bi-specific ligands or adaptors (e.g. sCAR-EGF, bi-specific antibodies against fiber and EGFR) to target tumor cells and/or detarget normal cells, that is, to enable the viruses to specifically attach to receptors on the tumor cell and enter tumor cells without infecting normal cells, all described above.
Capsid modifications include mutation, extension (e.g. RGD or pK sequences), substitution and/or switching between virus types of one or more of the relevant surface proteins. Specific ligands to cell surface receptors need to be genetically engineered into the capsid locale; while bi-specific ligands or adapters are attached to the virus in vitro or can be expressed in the host by gene transfer. These various strategies to redirect targeting/detargeting (Table 2) have been reported to significantly enhance the selective infection of tumor cells by CRAds and overcome the lack of CAR. [89] [90] [91] Most of these strategies are also applicable to replication-defective Ad vectors for gene transfer. The capsid modifications may also provide an additional benefit of shielding from humoral response.
Tumor-selective replication. Replication of Ad after infection depends on the ability of the virus to hijack the host cellular machinery. Studies in recent years indicate that replication selectivity can be achieved by mutating the viral genes or functions that are required for efficient viral replication or toxicity in normal cells but not in tumor cells, so that the virus can replicate in tumor cells that have disruptions in normal homeostatic pathways, such as p53, p16/RB and RAS/PKR or IFN/PKR pathways [92] [93] [94] [95] [96] [97] [98] (Table 3 ). Most of the CRAds which have been developed to date are based on or incorporate such strategies. The original CRAd prototype of this class, ONYX-015 (or dl1520), contains a deletion in E1B-55kD which plays a critical role in viral replication by binding to and inactivating p53, and was thus expected to be able to replicate in p53-deficient tumor cells but be unable to replicate in normal cells which express wild-type p53. 97 However, subsequent studies revealed that the p53-E1B interactions and their roles in CRAd oncolytic selectivity are more complex than originally thought and remain to be fully elucidated. Unexpectedly, ONYX-015 could replicate in some tumor cells that retain wild-type p53, and in other tumor cells its replication required E1B-55kD late function regardless of the p53 status. 99 It was subsequently shown that the tumor selectivity of ONYX-015 appeared to be determined, not by p53 in fact, but by the export of late viral RNAs, a function requiring E1B-55kD in normal cells but not in tumor cells, providing an explanation to the observed independence on p53 by the viral replication selectivity. 95, 100 It should be noted that the deletion of E1B-55kD, while conferring the virus tumor selectivity, also affects other events of the viral life cycle and may lead to reduced oncolytic effects, and in some cases the efficient induction of cell death by Ads seems to require binding of E1B-55kD and p53. 101 In similar CRAds in which the pRbbinding domain of E1A was deleted (e.g. AdDelta24), p53 expression from the virus increased CRAd potency. 102 Preliminary in vitro results suggested that this also increased CRAd safety. Interestingly, it was shown that these effects depended on the E1B-55kD protein retaining its ability to interact with p53; this interaction was abolished by the mutation of a single amino acid (R240A) in E1B-55kD which abrogated its capacity to bind p53. 103 Strategies to achieve tumor selectivity of CRAds are not limited to modifications of viral genes but have been expanded to modulations of cellular gene expression and activity, usually by components transferred by the CRAds themselves. 104 Tumor-selective promoters. An increasing number of genes, such as AFP, prostate-specific antigen, human CEA and TERT, are known to be upregulated in tumors despite limited or no expression in normal adult tissues. Using the promoters of tumor-specific genes to regulate Abbreviations: EGF, epidermal growth-factor; HER2, Human EGFR-type 2; FGF, fibroblast growth factor; FGFR1, FGF receptor 1.
Developments in adenoviruses and immunotoxins ZR Yang et al the expression of Ad genes, such as E1A and E1B55KD, is important in the development of highly tumor selective CRAds, [105] [106] [107] which can cause more than 10 000-fold increase in viral replication in AFP-expressing tumor cells but minimal toxicity to normal (AFP-negative) cells, 105 and showed safety and efficacy in clinical studies. 108 Nevertheless, the strategy of using tumor-specific promoters has also experienced some problems. The cellular promoters placed in and affected by the viral genome are often leaky, which could allow non-specific viral replication, or sometimes they are too weak to affect sufficient expression of the genes under their control. One approach to protect the promoters from transcriptional interference by adenoviral backbone sequences is to incorporate insulator sequences, DNA sequence elements that could block the interactions between promoters and enhancers. 109 Modifications to improve CRAd -capsid protein modification for targeting and shielding The effectiveness of Ads, both as CRAds and nonreplicative vectors, is limited by the host humoral response which generates pre-existing neutralizing antibodies against Ads' and through the lack of the Ad receptor CAR on tumor cells. Genetic and nongenetic strategies are being developed to overcome these limitations. 25, 110 A combination of genetic strategies intended to alleviate both the lack of CAR on tumor cells and the humoral response they induce, have shown promising results. Incorporation of integrin-binding RGD peptide in the capsid fiber knob of AdDelta24, resulted in the AdDelta24-RGD vector, and markedly augmented the CRAds' infectivity and oncolytic activity against tumor cells.
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Then 'self-molecules', which await identification and validation, were incorporated into the capsid protein pIX in order to provide a uniform shielding from the humoral response. Indeed, the pIX locale tolerated genetic incorporation of fairly large test proteins such as GFP and herpes simplex virus-thymidine kinase (HSV-TK), and preliminary tests with a pIX-TK Ad in mice previously immunized with wild-type Ad5 showed a markedly reduced binding by neutralizing antibodies from the sera to the pIX-TK Ad than to the control Ad, which suggest that this shielding concept is feasible. 112 Such improvements would also be applicable to nonreplicative adenoviral vectors.
Enhancing effect of CRAds by gene silencing with siRNA. Like replication-deficient Ads, CRAds can be armed with siRNAs aimed at knocking-down expression of tumor-promoting genes. In fact, delivery of siRNA by CRAds may have additional benefits of restricted siRNA expression in tumors and providing antitumor effects on top of oncolysis. Earlier experiments demonstrated the feasibility of delivering siRNAs by CRAds to specifically knock-down test target gene expression in cancer cells, 113 and some recent studies showed that ONYX-411 which delivers a mutant K-ras siRNA transgene markedly enhanced the potency of the CRAd to specifically inhibit the growth of cancer cells and suppress tumor growth in mice. 88 On the other hand, CRAds can be made more selective and effective by expressing and protecting (or averting) positive (or negative) regulators of tumor-specific replication and antitumor activity. For instance, expression by CRAds of p53 variants resistant to degradation by MDM2 or HPV's E6 protein in cancer cells enhanced tumor-selective replication and oncolysis. 114, 115 Further benefits should also be achievable by suppressing negative factors with siRNAs. Such studies could identify and examine potential inhibitors of oncolysis as targets for silencing by RNAi.
Immunotoxins
A new class of antitumor agents, called immunotoxins, are ligand-toxin hybrid molecules which consist of a Abbreviation: BAX: a member of the Bcl-2 protein subfamily, which facilitates apoptosis. #, p300/CBP, co-activator of p53 activity.
tumor cell-binding moiety (antibody or ligand) linked to another tumor cell-killing moiety (a toxin), and combine the potency of the toxin with the specificity of the attached ligand. 16 An immunotoxin can kill cancer cells through the binding of specific cell surface receptors, internalization and the delivery of the toxin moiety to the cell cytoplasm. The toxin then catalytically inhibits a critical cell function, usually protein synthesis, and triggers cell death. It was originally suggested by Paul Ehrlich as the 'magic bullet' in 1906 and was first shown to be potent tumor cell killer in the 1970s. 116 Owing to the complexities of tumor biology, the heterogeneity of human tissues and other technical issues, it seems unlikely for some common therapeutic molecules like cytokines or chemotherapeutic agents alone to get sufficient and reliable antitumor effects. Hence, further research and development of much more potent therapeutic molecules such as immunotoxins have been pursued. Previous data showed that a single immunotoxin could kill a tumor cell, compared with 105 molecules of a chemotherapeutic drug. 117 The high potency of immunotoxins may be, in part, due to the toxin domain of immunotoxins working independently of the cell cycle, evading most of the obstacles to standard chemo-or radio-therapy, and some other gene therapy approaches. Like other areas of biomedicine, growing interest and augmented efforts directed at bringing immunotoxins to the clinic in recent years have led to major advances in our understanding of how immunotoxins work and a rapid increase in the number of clinical trials on immunotoxins. 13, 16, 118, 119 Construction of immunotoxins Multiple factors influence the in vivo antitumor activity of recombinant immunotoxins (rIT) and need to be considered. 16, 118 To design an immunotoxin, one should confirm the type and stage at which the cancer cells will be the best targets, analyze the tumor specificity of the antigen that is targeted by the recombinant antibody, as well as the affinity of immunotoxins for the cell type and the ability of the immunotoxins to penetrate and enter into normal tissues and tumor cells. Besides, the stability, immunogenicity and side effects of immunotoxins should also be considered. Anti-immunotoxin antibodies can reduce the effectiveness of immunotoxins by accelerating their clearance from the circulation or by blocking the functional domains of the targeting module or toxin. The common side effects of immunotoxins include hepatotoxicity, hypoalbuminemia, vascular leak syndrome and myalgias. 119 First-generation immunotoxins consisted of monoclonal antibodies that were biochemically linked to whole toxin units. These immunotoxins were heterogeneous and required the separate production of antibody and toxin. However, clinical results using these early immunotoxins were less than remarkable 116, 120 and their huge size made their penetration into solid tumors slow. Subsequently, it was realized that the cell-binding domains of bacterial toxins could be removed and replaced with the Fv portions of antibodies or with growth factors by genetic engineering. These rIT which consist of genetically linked truncated toxins were less immunogenic, with a lower cost and a smaller size, significantly increasing their penetration rate into solid tumors. 121 In the 1990s, a new type of disulfide-stabilized Fv (dsFV) molecules were designed in which the light and heavy chains were held together by a disulfide bond. Compared with the single-chain toxins, dsFV-based immunotoxins do not aggregate and have remarkable stability at 371C (several days or longer). 122 Since entry into bulky tumor masses is slow and the single-chain rIT had only a relatively short half-life of 3-4 h, dsFV-based rIT also overcame a major obstacle for immunotoxin in treating solid tumors. 120 The antibodies that have been most widely used in immunotoxins are murine monoclonal antibodies belonging to the IgG isotype. 118 A variety of toxins, mainly ribosome-inactivating or translation-inhibiting peptides from plants, fungi or bacteria, have been developed; structurally optimized for in vitro stability, activity and safety; and evaluated in vivo in animal and clinical trials (Table 4) , among which ricin, Pseudomonas exotoxin (PE) and diphtheria toxin (DT) are most frequently used. 119 Current applications of immunotoxins An increasing number of preclinical studies and clinical trials of immunotoxins have been conducted and are underway for cancer therapies. 16. Various immunotoxins have been developed to treat chemotherapy-relapsed tumors, and especially refractory hematological malignancies, in which malignant cells are often intravascular and more accessible to immunotoxins including hairy cell leukemia (HCL), Hodgkin's lymphoma, T-cell lymphoma and chronic lymphocytic leukemia (CLL). 119 In 2000, the FDA approved Mylotarg, the first immunotoxin drug which consisted of a humanized anti-CD33 antibody conjugated to calicheamicin -a small bacterial toxin isolated from Micromonospora echinospora ssp calichensis that is at least 1000-fold more potent than conventional cytotoxic chemo agents, for the treatment of refractory acute myeloid leukemia. [123] [124] [125] This success has greatly encouraged the development of new immunotoxins and the search for new therapeutic targets. Currently, a number of clinical trials of rITs, particularly novel dsFV-based immunotoxins including those targeting the less accessible solid tumors are in progress (Table 5) .
Among which, the most striking responses À 61% complete remission (CR), 81% overall response -in phase-I testing came from an rIT named BL22 in HCL. 120, 126, 127 BL22, or RFB4(dsFv)-PE38, which contains a truncated PE (PE38) fused to an Fv fragment of an anti-CD22 monoclonal antibody, is the first rIT that has been reported to cause such a high rate of CR in chemoresistant HCL. It is currently undergoing phase-II trials in HCL and phase-I trials in both CLL and acute lymphocytic leukemia, in which BL22 is administered in a modified protocol in an effort to prevent hemolytic uremic syndrome (HUS). 127 Another relatively successful case is SS1(dsFv)-PE38 (SS1P), a recombinant antimesothelin immunotoxin, now in two phase-I clinical trials at National Cancer Institute (NCI). SS1P has shown strong antitumor activity against mesothelin-expressing tumors in animal models, and significant efficacy in patients with mesotheliomas and ovarian cancers. 16 Phase-I and -II trials of IL4-PE38KDEL, targeting IL-4 receptors on tumor cells via IL-4, showed some CRs and partial remission, but the associated toxicity was unacceptable. 16 Likewise, Erb-38, which targets the Her2/ neu protein expressed on breast cancers via antibody, was found to produce liver toxicity at very low doses in a Phase-I trial due to the presence of Her2/neu on human liver cells. 120, 128 Continual development of these rITs would require resolving the toxicity/nonspecificity issue. By contrast, the other two cytokine-fused immunotoxins, IL13-PE38QQR (targeting IL-13 receptor) and TGFa-PE38 (targeting EGFR), are both much better tolerated and have induced CRs and prolonged survival times in some patients during phase-I and phase-II trials. 16, [129] [130] [131] Phase-III clinical trial of IL13-PE38QQR for those with glioblastoma multiforme (GBM) at first recurrence or progression is underway.
Several rITs that target the Lewis Y antigen, which is found on most colon, stomach and pancreatic cancer cells, have also been evaluated in clinical trials. From LMB-1 (B3(mAb)-PE38), to modified LMB-7 (B3(Fv)-PE38) and LMB-9 (B3(dsFv)-PE38), only limited Abbreviations: a.a., amino acid; EF-2, elongation factor 2; REDLK, Arg-Glu-Asp-Leu-Lys; KDEL, Lys-Asp-Glu-Leu. 12, 16, 116, 119, 120, 126, 134 .
Developments in adenoviruses and immunotoxins ZR Yang et al antitumor benefits were reported with them in completed Phase-I clinical trials for colon, stomach and pancreatic cancers, which may be due partly to the low affinity of the immunotoxin for this carbohydrate antigen, and the presence of this antigen on kidney cells. 16, 132 While LMB-2 (anti-Tac(Fv)-PE38), which targets the a subunit of IL2R (CD25), has produced some CRs in HCL and partial remissions in Hodgkin's lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia and HCL patients in Phase-I trials. 133, 134 Phase-II trials are currently underway in patients with CLL and cutaneous T-cell lymphoma.
Although great progress has been made in the preclinical studies of immunotoxins, it often appears that the clinical anticancer efficacies are not as potent as predicted from laboratory results. Many issues and problems have arisen due to the inaccessibility and heterogeneity of the target tumor cells and its associated endothelium. The specificity, stability, humoral responses and side effects induced by immunotoxins remain to be resolved, requiring more research and development as well as patience. A promising strategy has yet to be extensively explored which combines immunotoxins with gene therapy approaches, for example, by using vectors to deliver immunotoxin genes.
Summary
The accelerated translation of cancer gene therapy from laboratory bench to clinical bedside has been driven by the tremendous advances in biological sciences and technologies following the dawning of the post-genome era. Augmented research and development efforts across disciplines have resulted in, among other things, our better understanding of the genetic, molecular and cellular mechanisms of oncogenesis, the immune system and vector-host interactions, and have led to the development of superior vectors and technologies for gene manipulation, delivery and targeting. Among the various approaches to cancer gene therapy, viruses, especially Ads and retroviruses, play central roles. Replication-defective Ads continue to be developed and employed as one of the major vector systems for transferring therapeutic genes; and lately, there is renewed interest in developing tumor-specific replicating Ads to lyse cancer cells. One of the other approaches, immunotoxins, which consists of a moiety (an antibody or ligand) for tumor cell targeting and another (a toxin) for tumor cell killing, is also being actively investigated and holds great promise for future cancer-specific cell death.
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